Monsanto Acquires Select Assets of Agradis, Inc. to Support Work in Agricultural Biologicals

     Monsanto Acquires Select Assets of Agradis, Inc. to Support Work in
                           Agricultural Biologicals

Monsanto also signs research collaboration agreement with and makes equity
investment in Synthetic Genomics Inc., co-founding company of Agradis, Inc.

PR Newswire

ST. LOUIS, Jan. 30, 2013

ST. LOUIS, Jan. 30, 2013 /PRNewswire/ --Monsanto Company today announced it
has purchased select assets of Agradis, Inc. (Agradis), a privately held
company focused on developing sustainable agricultural solutions. Monsanto's
purchase includes the Agradis name and its collection of microbes that can
improve crop productivity. Monsanto has also acquired the company's R&D site
in La Jolla, California. Additional details were not disclosed.

Agradis was formed in 2011 by Synthetic Genomics Inc (SGI), a privately held
company led by J.Craig Venter, Ph.D. Founder and CEO, dedicated to developing
genomic-driven solutions to address global challenges, and Plenus, S.A. de
C.V. (Plenus) a Mexico-based investing and management company headed by
Alfonso Romo, which has extensive experience in a variety of business areas,
including agribusiness. The assets of Agradis not purchased by Monsanto
include castor and sweet sorghum breeding and genetic optimization
technologies, as well as a novel product used to prevent fungal growth on
fruits and vegetables. These assets will continue to be advanced by SGI and
Plenus in a new company, AgraCast.

"Agradis' collection of plant associated microbes will support Monsanto's
efforts to provide farmers with sustainable biological products to improve
crop health and productivity," said Steve Padgette, Monsanto R&D investment
strategy lead. "We value the expertise and capabilities the Agradis team
brings to Monsanto as we continue to build on this exciting area of research."

Dr. Venter stated, "SGI and Plenus formed Agradis with the belief that our
extensive expertise in microbial genomics could accelerate advances in
agriculture. We are pleased that Monsanto realizes the potential of the
Agradis science and technology as evidenced by their acquisition of some key
assets of the company. We look forward to working with Monsanto to continue to
generate innovation in agribusiness."

Today's announcement also includes an agricultural research agreement between
Monsanto and SGI. The multi-year research collaboration will focus on the
analysis of microbe-plant communities and screening for beneficial
microorganisms that could be used to develop additional biological products to
improve agricultural productivity. Monsanto has also made an equity investment
in SGI. Terms of the investment were not disclosed.

"We look forward to bringing together the genomics strength of Monsanto,
Agradis and SGI to identify new agricultural solutions," Padgette added. "We
share a common vision that sustainable agricultural products can help meet
growing demand, and Monsanto views SGI as an excellent partner in helping
bring innovation to growers." 

Monsanto launched the agricultural biologicals platform of its research and
development pipeline last year with the introduction of BioDirect™ technology.
To learn more about Monsanto's agricultural biologicals platform, visit:

About Monsanto Company
Monsanto Company is a leading global provider of technology-based solutions
and agricultural products that improve farm productivity and food quality.
Monsanto remains focused on enabling both small-holder and large-scale farmers
to produce more from their land while conserving more of our world's natural
resources such as water and energy. To learn more about our business and our
commitments, please visit: Follow our business on Twitter^®
at, on the company blog, Beyond the Rows® at, or subscribe to our News Release RSS Feed.

About Agradis, Inc.
Agradis, a privately held agricultural company based in San Diego, CA, is
focused on developing and commercializing products to improve crop production
using new scientific and technology advances in genomics. For more information
please visit

About Synthetic Genomics Inc.
SGI, a privately held company founded in 2005, is dedicated to developing and
commercializing genomic-driven solutions to address global energy and
environment challenges. The company's main research and business programs are
currently focused on the following major bioenergy areas: designing advanced
biofuels with superior properties compared to ethanol and biodiesel;
harnessing photosynthetic organisms to produce value added products directly
from sunlight and carbon dioxide; developing new biological solutions to
increase production and/or recovery rates of subsurface hydrocarbons and
developing high-yielding, more disease resistant and economic feedstocks. For
more information go to

Monsanto Cautionary Statements Regarding Forward-Looking Information:

Certain statements contained in this release are "forward-looking statements,"
such as statements concerning the company's anticipated financial results,
current and future product performance, regulatory approvals, business and
financial plans and other non-historical facts. These statements are based on
current expectations and currently available information. However, since these
statements are based on factors that involve risks and uncertainties, the
company's actual performance and results may differ materially from those
described or implied by such forward-looking statements. Factors that could
cause or contribute to such differences include, among others: continued
competition in seeds, traits and agricultural chemicals; the company's
exposure to various contingencies, including those related to intellectual
property protection, regulatory compliance and the speed with which approvals
are received, and public acceptance of biotechnology products; the success of
the company's research and development activities; the outcomes of major
lawsuits and the previously-announced SEC investigation; developments related
to foreign currencies and economies; successful operation of recent
acquisitions; fluctuations in commodity prices; compliance with regulations
affecting our manufacturing; the accuracy of the company's estimates related
to distribution inventory levels; the company's ability to fund its short-term
financing needs and to obtain payment for the products that it sells; the
effect of weather conditions, natural disasters and accidents on the
agriculture business or the company's facilities; and other risks and factors
detailed in the company's most recent Form 10-K Report to the SEC. Undue
reliance should not be placed on these forward-looking statements, which are
current only as of the date of this release. The company disclaims any current
intention or obligation to update any forward-looking statements or any of the
factors that may affect actual results.

Contact: Monsanto: Sara Miller (314-694-5824)
SGI: Heather Kowalski (858-754-2910)

SOURCE Monsanto Company

Press spacebar to pause and continue. Press esc to stop.